Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.025
Bid: 2.95
Ask: 3.10
Change: 0.15 (5.22%)
Spread: 0.15 (5.085%)
Open: 2.875
High: 3.025
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Fri, 20th Nov 2020 14:51

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Land Securities Group PLC - London-based commercial property developer - Chief Executive Officer Mark Allan buys 45,695 shares at GBP6.82, worth GBP311,772, on Thursday. Landsec last week reported a wider interim loss and a fall in net asset value but reinstated its dividend.

----------

SSE PLC - electricity utility based in Perth, Scotland - Colin Nicol, outgoing managing director of electricity distribution business, SSEN Distribution, sells 18,212 shares at GBP14.11, worth GBP256,990, on Wednesday.

----------

RSA Insurance Group PLC - London-based general insurance - Chief Legal Officer Charlotte Heiss sells 29,968 shares at GBP6.75, worth GBP202,344, on Thursday. RSA on Wednesday said it has reached an agreement to be sold and split up in a deal with a two-headed consortium which values the former Royal & Sun Alliance Insurance Group at GBP7.2 billion.

----------

Spirent Communications PLC - Crawley, England-based provider of testing, analytics and security for telecommunications networks - Dean Ritchie, associate of Chief Financial Officer Paula Bell, buys 50,000 shares at GBP2.57, worth GBP128,740, on Thursday. Bell now interested in 363,884 shares.

----------

Jardine Matheson Holdings Ltd - Hong Kong-headquartered holding company with interests in retail, property, hotels and motor dealerships - Ruby Weatherall, associate of Director Percy Weatherall, sells 3,100 shares at USD51.35, worth USD159,193, in Singapore on Thursday.

----------

H&T Group PLC - Surrey, England-based pawnbroker - CFO Richard Withers buys 10,000 shares for 227.4 pence, worth GBP22,740, on Wednesday.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Non-Executive Chair Peter Jensen buys 100,000 shares at 14p, worth GBP14,000, on Thursday.

----------

easyJet PLC - Luton Airport-based budget airline - Non-Executive Director Nicholas Leeder buys 1,346 shares mostly at GBP7.53, worth GBP10,140, on Thursday.

----------

Henderson High Income Trust PLC - investment trust aiming for high-income stream and prospects of capital growth - Director Jeremy Rigg buys 10,000 shares at GBP1.46, worth GBP14,605, on Friday.

----------

Dunedin Enterprise Investment Trust PLC - invests in UK mid-market companies - Directors sell shares as part of company's tender offer at GBP3.85 on November 12. Brian and Fionnlagh Finlayson sell 27,572 shares. Duncan, Rosemary and Victoria Budge sell 12,449 shares. Angela and David Lane sell 4,307. Company bought back 2.5 million shares in total, spending about GBP9.8 million.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Sep 2016 09:46

Numis reiterates 'buy' on Allergy Therapeutics after full year results

(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ

Read more
13 Jul 2016 08:43

Allergy Therapeutics Expects Revenue Rise Despite Euro Weakening

Read more
8 Jul 2016 14:02

Allergy Therapeutics sees good results from Acarovac Plus

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house

Read more
8 Jul 2016 07:26

Allergy Therapeutics Welcomes Positive Follow-Up Results For Acarovac

Read more
27 Jun 2016 09:51

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Read more
27 Jun 2016 09:06

Allergy Therapeutics Sees Delayed US Market Launch For GrassMATAMPL

Read more
10 Jun 2016 07:41

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Read more
9 May 2016 06:57

Allergy Therapeutics Gets Positive Birch Pollen Treatment Results

Read more
5 Apr 2016 08:12

NetScientic Poaches New Finance Boss From Allergy Therapeutics

Read more
17 Mar 2016 09:08

Allergy Therapeutics Finance Director Ian Postlethwaite Resigns

Read more
10 Mar 2016 09:33

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Read more
8 Mar 2016 10:59

Allergy Therapeutics Profit Drops On Higher Costs As Revenue Edges Up

Read more
18 Feb 2016 08:08

Allergy Therapeutics Completes Enrolment For Grass Pollen Drug Study

Read more
13 Jan 2016 09:38

Allergy Therapeutics Revenue Up In First Half, Full Year Seen In Line

Read more
7 Dec 2015 07:54

Allergy Therapeutics Begins US Phase II Study Of Grass Allergy Vaccine

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.